The life sciences research technology developer has received funding in a series A round co-led by corporate investor ABclonal.
Biotech company ABclonal has co-led a RMB200m ($31m) series A round for China-based life sciences research equipment maker Monad, DealStreetAsia reported on Wednesday, citing a company statement.
The round was co-led by investment firm Lucion and also featured venture capital fund Wuxi Capital.
Co-founded by Zhuhai Nanshan Investment, Monad provides biological instruments and antibody research technology in addition to reagents and in-vitro diagnostics tools. It is headquartered in the city of Suzhou but has facilities in Shanghai and Wuhan.
The…
